The clinical value of serum tumor markers combined PET/CT diagnosis on non-small cell lung cancer
Genlin Shi,Zhaoyun Xia,Xixu Zhu
2013-01-01
Abstract:Objective To investigate the clinical value of serum tumor markers combined positron emission tomography and computed tomography (PET/CT) diagnosis on non-small cell lung cancer (NSCLC). Methods 65 cases of patients with suspected lung cancer of X-ray examination were considered as NSCLC group, in which 39 cases were males, 26 cases were females, the age was from 38 to 75 years old and the mean one was (56.4±6.5) years old. 30 patients with benign lung disease patients were selected as benign lung disease group, in which 18 cases were males, 12 cases were females, the age was from 34 to 67 years old and the mean one was (55.2±6.0) years old; 30 healthy subjects were as the healthy control group, in which 17 cases were males, 13 cases were females, the age was from 36 to 74 years old and the mean one was (55.3±5.7) years old. The NSCLC patients hospitalized line 18F-FDG PET/CT and serum tumor markers in check, and cells or pathological results. Healthy control group and benign lung disease group, only test serum tumor markers. The detection of serum tumor markers: Serum carcinoembryonic antigen (CEA), cytokeratin fragment antigen (Cyfra21-1), neuron-specific enolase enzyme (NSE), the squamous cell antigens (SCCAg), tissue polypeptide specific antigen (TPS), gastrin-releasing peptide precursor (Pro-GRP). Result Benign lung disease serum TPS, NSE level was significantly higher than the healthy control group (P<0.01), TPS positive rate was significantly higher than the healthy control group (P<0.05). NSCLC group, serum TPS CYFRA21-1, NSE, Pro-GRP, CEA, SCCAg levels and the positive rate was significantly higher than the healthy control group and lung benign disease group (P <0.01). The sensitivity, specificity, positive predictive value and negative predictive value of PET/CT combined with tumor markers were higher than simple tumor markers. Conclusion Serum tumor markers joint 18F-FDG PET/CT imaging has a higher diagnostic value, could better guide clinical treatment of NSCLC.